 Timothy Waxweiler
Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Four-Dimensional Computed Tomography | 3 | 2021 | 38 | 0.690 |
Why?
| | Pulmonary Ventilation | 3 | 2021 | 82 | 0.560 |
Why?
| | Re-Irradiation | 1 | 2016 | 9 | 0.500 |
Why?
| | Brain Neoplasms | 4 | 2023 | 1331 | 0.490 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 4 | 2021 | 149 | 0.400 |
Why?
| | Lung Neoplasms | 4 | 2023 | 2668 | 0.390 |
Why?
| | Sarcoma | 1 | 2015 | 207 | 0.370 |
Why?
| | Radiotherapy, Intensity-Modulated | 3 | 2018 | 142 | 0.360 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1062 | 0.350 |
Why?
| | Radiotherapy, Conformal | 3 | 2017 | 74 | 0.340 |
Why?
| | Prostatic Neoplasms | 5 | 2015 | 981 | 0.320 |
Why?
| | Radiation Pneumonitis | 2 | 2021 | 31 | 0.310 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 1150 | 0.300 |
Why?
| | SEER Program | 6 | 2015 | 230 | 0.230 |
Why?
| | Head and Neck Neoplasms | 2 | 2022 | 561 | 0.220 |
Why?
| | Risk Assessment | 1 | 2015 | 3752 | 0.220 |
Why?
| | Oncogene Addiction | 1 | 2023 | 6 | 0.190 |
Why?
| | Antineoplastic Agents | 3 | 2023 | 2219 | 0.170 |
Why?
| | Neoplasm Staging | 4 | 2018 | 1475 | 0.150 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2023 | 431 | 0.150 |
Why?
| | Proto-Oncogene Proteins | 1 | 2023 | 625 | 0.150 |
Why?
| | Radiosurgery | 1 | 2022 | 399 | 0.140 |
Why?
| | Carcinoma, Renal Cell | 1 | 2021 | 230 | 0.140 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 344 | 0.140 |
Why?
| | Smokers | 1 | 2018 | 138 | 0.130 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 44 | 0.120 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 415 | 0.120 |
Why?
| | Salivary Gland Neoplasms | 1 | 2016 | 39 | 0.120 |
Why?
| | Respiration | 1 | 2017 | 207 | 0.120 |
Why?
| | Neoplasm Grading | 2 | 2014 | 311 | 0.120 |
Why?
| | Treatment Outcome | 8 | 2023 | 11794 | 0.120 |
Why?
| | Analysis of Variance | 2 | 2015 | 1300 | 0.110 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 76 | 0.110 |
Why?
| | Testicular Neoplasms | 1 | 2016 | 111 | 0.110 |
Why?
| | Organ Sparing Treatments | 1 | 2015 | 37 | 0.110 |
Why?
| | Medically Uninsured | 1 | 2015 | 132 | 0.110 |
Why?
| | Oligodendroglioma | 1 | 2014 | 15 | 0.110 |
Why?
| | Brachytherapy | 1 | 2015 | 132 | 0.110 |
Why?
| | Prognosis | 4 | 2018 | 4330 | 0.110 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2014 | 222 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1192 | 0.100 |
Why?
| | Astrocytoma | 1 | 2014 | 130 | 0.100 |
Why?
| | Retrospective Studies | 6 | 2017 | 17330 | 0.100 |
Why?
| | Insurance, Health | 1 | 2015 | 311 | 0.090 |
Why?
| | Humans | 19 | 2023 | 145785 | 0.090 |
Why?
| | Benzimidazoles | 1 | 2013 | 189 | 0.090 |
Why?
| | Retinol-Binding Proteins | 1 | 2011 | 17 | 0.090 |
Why?
| | Eye Abnormalities | 1 | 2011 | 17 | 0.090 |
Why?
| | Infant | 2 | 2016 | 10091 | 0.090 |
Why?
| | Chemoradiotherapy | 1 | 2013 | 239 | 0.080 |
Why?
| | Medicaid | 1 | 2015 | 467 | 0.080 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2013 | 134 | 0.080 |
Why?
| | Aged | 11 | 2023 | 26217 | 0.080 |
Why?
| | Lymph Nodes | 1 | 2014 | 509 | 0.080 |
Why?
| | Eye Proteins | 1 | 2011 | 92 | 0.080 |
Why?
| | Child, Preschool | 2 | 2016 | 11868 | 0.080 |
Why?
| | Survival Rate | 4 | 2016 | 2094 | 0.080 |
Why?
| | Eye | 1 | 2011 | 112 | 0.080 |
Why?
| | Male | 15 | 2023 | 73012 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 442 | 0.080 |
Why?
| | Adolescent | 4 | 2016 | 22577 | 0.070 |
Why?
| | Algorithms | 1 | 2017 | 1851 | 0.070 |
Why?
| | Melanoma | 1 | 2015 | 762 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1969 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2015 | 853 | 0.070 |
Why?
| | Prospective Studies | 2 | 2018 | 8078 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 971 | 0.070 |
Why?
| | Middle Aged | 10 | 2023 | 36309 | 0.060 |
Why?
| | United States | 5 | 2015 | 16126 | 0.060 |
Why?
| | Radiotherapy Dosage | 2 | 2018 | 288 | 0.060 |
Why?
| | Adult | 7 | 2023 | 40882 | 0.060 |
Why?
| | Child | 2 | 2016 | 22740 | 0.060 |
Why?
| | Young Adult | 3 | 2016 | 14254 | 0.060 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 868 | 0.050 |
Why?
| | Propensity Score | 2 | 2016 | 377 | 0.050 |
Why?
| | Female | 9 | 2023 | 79045 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 688 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2015 | 6465 | 0.050 |
Why?
| | Prostate-Specific Antigen | 2 | 2014 | 161 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2016 | 5428 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2015 | 1330 | 0.040 |
Why?
| | Central Nervous System | 1 | 2023 | 282 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2023 | 635 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 467 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2016 | 8347 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2023 | 3916 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 782 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 40 | 0.030 |
Why?
| | Cetuximab | 1 | 2018 | 111 | 0.030 |
Why?
| | Age Factors | 2 | 2016 | 3346 | 0.030 |
Why?
| | Phthalazines | 1 | 2018 | 63 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 410 | 0.030 |
Why?
| | Skin Ulcer | 1 | 2015 | 15 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 375 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1505 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1271 | 0.030 |
Why?
| | Radiation Protection | 1 | 2015 | 41 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 47 | 0.030 |
Why?
| | Prostatectomy | 1 | 2014 | 94 | 0.020 |
Why?
| | Comet Assay | 1 | 2013 | 14 | 0.020 |
Why?
| | HT29 Cells | 1 | 2013 | 37 | 0.020 |
Why?
| | Disease Progression | 1 | 2021 | 2865 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2013 | 65 | 0.020 |
Why?
| | HCT116 Cells | 1 | 2013 | 76 | 0.020 |
Why?
| | Radiotherapy | 1 | 2014 | 206 | 0.020 |
Why?
| | Time Factors | 2 | 2014 | 7134 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2014 | 336 | 0.020 |
Why?
| | Camptothecin | 1 | 2013 | 138 | 0.020 |
Why?
| | Research Design | 1 | 2018 | 1139 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2014 | 770 | 0.020 |
Why?
| | Fluorouracil | 1 | 2013 | 231 | 0.020 |
Why?
| | Microscopy, Interference | 1 | 2011 | 8 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 1042 | 0.020 |
Why?
| | Tumor Burden | 1 | 2013 | 325 | 0.020 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2011 | 20 | 0.020 |
Why?
| | Refractive Errors | 1 | 2011 | 36 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 680 | 0.020 |
Why?
| | S Phase | 1 | 2011 | 78 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1329 | 0.020 |
Why?
| | Glioblastoma | 1 | 2014 | 354 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2015 | 1115 | 0.020 |
Why?
| | Organ Size | 1 | 2011 | 461 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2011 | 319 | 0.020 |
Why?
| | DNA Damage | 1 | 2013 | 437 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2013 | 936 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 2110 | 0.020 |
Why?
| | Lung | 1 | 2021 | 4116 | 0.020 |
Why?
| | Histones | 1 | 2013 | 666 | 0.020 |
Why?
| | Colorado | 1 | 2015 | 4556 | 0.010 |
Why?
| | Mice | 2 | 2013 | 18358 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 3130 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5925 | 0.010 |
Why?
| | Apoptosis | 1 | 2011 | 2445 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 5995 | 0.010 |
Why?
| | Animals | 2 | 2013 | 38106 | 0.010 |
Why?
|
|
Waxweiler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|